XEN1701 is a Xenon Pharmaceuticals Inc. program. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Sponsor: Xenon Pharmaceuticals Inc. (XENE). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| Avoro Capital Advisors | 5,777,777 | $348.7 million | filed August 14, 2026 |
| OrbiMed Advisors | 892,471 | $53.9 million | filed August 14, 2026 |
| Baker Bros. Advisors | 370,208 | $22.3 million | filed August 14, 2026 |
| Redmile Group | 229,374 | $13.8 million | filed August 14, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
No upcoming catalyst is on our calendar for XEN1701; no FDA decisions are on record below.
No FDA decision for XEN1701 is in our archive yet.
Xenon Pharmaceuticals Inc. (XENE).
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.